General health and function Not assessed · children and adolescents with a diagnosis of autism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · people with ADHD and epilepsy
Omega‐3 (with risperidone and previous ASM) showed no clear difference in proportion of people achieving 50% or greater reduction in monthly… compared with risperidone and previous ASM only (low certainty).
1 finding from 1 review
ADHD symptoms · people with ADHD and epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse drug events · people with ADHD and epilepsy
Omega‐3 (with risperidone and previous ASM) showed no clear difference in proportion of people experiencing adverse drug events compared with risperidone and previous ASM only (low certainty).
1 finding from 1 review
Seizure frequency · people with ADHD and epilepsy
1 finding from 1 review
Proportion of individuals withdrawing from treatment · people with ADHD and epilepsy
Omega‐3 (with risperidone and previous ASM) showed no clear difference in proportion of individuals withdrawing from treatment compared with risperidone and previous ASM only (low certainty).
1 finding from 1 review
Seizure severity · people with ADHD and epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response: no clinically significant response in mental state: 20% to 50% reduction in PANSS total score · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + RISPERIDONE changes clinical response: no clinically significant response in mental… compared with CLOZAPINE + SULPIRIDE (Kong 2001) (very low certainty).
1 finding from 1 review
Weight gain · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + RISPERIDONE changes adverse effects: weight gain compared with CLOZAPINE + SULPIRIDE (Kong 2001) (very low certainty).
1 finding from 1 review
Clinical response: mean score/change in global state · people with treatment‐resistant schizophrenia
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · people with treatment‐resistant schizophrenia
1 finding from 1 review
Leaving the study early · people with treatment‐resistant schizophrenia
1 finding from 1 review
Service utilisation outcomes: hospital admission or days in hospital · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life/satisfaction with care for either recipients of care or carers: significant change in quality of life/satisfaction · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response: no clinically significant response in mental state · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + RISPERIDONE changes clinical response: no clinically significant response in mental… compared with CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010) (very low certainty).
1 finding from 1 review
Weight gain · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response: mean score/change in global state: mean CGI‐II Global improvement score (high = poor) Short term (6 weeks) · people with treatment‐resistant schizophrenia
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · people with treatment‐resistant schizophrenia
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + RISPERIDONE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010) (very low certainty).
1 finding from 1 review
Service utilisation outcomes: hospital admission or days in hospital · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found